ADVOCACY, COMMUNICATIONS & FUNDRAISING
The UN High-Level Panel to address policy incoherence Beyond WHO, a High-Level Panel was formed at the UN to discuss “the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health”. DNDi’s submission drew lessons from our experience – which serves as a practical illustration of how R&D can be conducted in the public interest, if a de-linked approach is
implemented, with R&D costs at a fraction of the traditional pharmaceutical business model. In addition, global responses to pandemic diseases and antibiotic resistance are swiftly being established. While it is encouraging that so many multiple processes are looking at the issue of global health innovation, the response is currently highly fragmented. Governments need to “join the dots” between multiple
frameworks and develop an overarching framework for all R&D actors and for all areas of public health importance. Going forward, DNDi will continue to engage with WHO, the G7, G20, and other UN processes, with a view to encouraging the taking of progressive steps towards this R&D framework, in order to ensure innovation with access.
ECTMIH 2015 and launch of new business plan: DNDi more committed than ever to neglected patients
In September 2015, the DNDi team attended the 9th European Congress on Tropical Medicine and International Health (ECTMIH) in Basel, Switzerland. ECTMIH brings together over 2,000 of the most distinguished scientists and experts in the field of tropical diseases. DNDi organized five symposia on visceral leishmaniasis, open source drug discovery, helminth infections, sleeping sickness, and mycetoma, as well as participating in seven other symposia. DNDi’s Executive Director, Dr Bernard Pécoul, also participated in the Roundtable ‘Challenges in Global health’ at the plenary closing session. On the margins of the conference, DNDi also organized a public event to unveil its new business plan for 2015-2023, to develop 16-18 treatments for neglected patients in need of safe, effective, affordable, and accessible medicines.
Attending DNDi’s new Business plan launch: Dr David Reddy, MMV, and Dr Robert Sebbag, Sanofi (top left); Dr Alwyn Gladwyn Zebron Mwinga, Zambia AIDS-Related Tuberculosis Project and patient representative at DNDi’ Board of Directors (top right) ; Dr Susanna Hausmann Muela, Swiss Agency for Development and Cooperation (bottom left); Dr Guy Morin, Mayor of Basel, and Dr Nkandu Luo, Gender Minister, Zambia (bottom right).
64 › DNDi Annual Report 2015